Amin Addetia

This study determines the structure of the 2026 Bundibugyo virus glycoprotein and identifies conserved epitopes for antibody therapeutics and pan-ebolavirus vaccines.

The paper shows repeated SARS-CoV-2 vaccine boosters elicit variant-specific memory B cells and neutralizing antibodies, suggesting immune imprinting can be overcome with updated vaccines.

This paper develops a stabilized MERS-CoV spike ferritin nanoparticle vaccine that elicits strong neutralizing antibodies in mice and non-human primates, providing protection against MERS-CoV infection.

This study designs miniproteins that inhibit MERS-CoV by targeting the spike protein, showing broad neutralization and protective efficacy in mice.

This study identifies a potent monoclonal antibody, MARV16, that broadly neutralizes Marburg virus and related viruses, with a cryo-EM structure revealing its mechanism of action.

This paper designs multivalent RBD nanoparticle vaccines that overcome immune imprinting and provide broad protection against SARS-CoV-2 variants and sarbecoviruses.

This study shows SARS-CoV-2 nsp1 inhibits translation in bat cells and human cells, revealing its broad activity across mammals.

HKU5 merbecoviruses use bat Pipistrellus abramus ACE2 and several artiodactyl ACE2s through a cryo-EM-defined binding mode distinct from other ACE2-using coronaviruses, showing independent evolution of ACE2 usage.

This study develops MERS-CoV vaccines using a protein nanoparticle platform, showing they induce strong neutralizing antibodies and protect mice against MERS-CoV challenge.

This study maps immunodominant sites on MERS-CoV spike glycoprotein targeted by infection-elicited antibodies in humans, showing peak neutralizing activity against S1 and RBD epitopes.

This study determines the structure of HKU1 spike RBD bound to TMPRSS2, identifies host receptor usage determinants, and shows the role of antibodies and glycan shielding in neutralization.

This study shows that immune imprinting from prior Wuhan-Hu-1 spike exposure persists after XBB.1.5 vaccine booster, with neutralizing antibodies dominated by pre-existing memory B cells.

The paper designs and characterizes trivalent miniprotein binders that neutralize SARS-CoV-2 variants with low pM IC50 values and provide prophylactic and therapeutic protection in mice.